Integra LifeSciences Holdings C
IART
Positions held
Your positionsIART isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Integra LifeSciences operates in the medical devices industry, which is experiencing growth due to increasing healthcare demands and technological advancements.
- Revenue increased by 7% compared to the prior quarter, reaching $419 million.
- Operating margin expanded to 4.6% in the latest quarter.
- The company has a high debt-to-equity ratio of 196.49, indicating potential financial risk.
- Net income was negative at -$4.617 million in the latest quarter, reflecting ongoing profitability challenges.
- The stock has a 'Strong Sell' signal with a score of -16.00, indicating bearish market sentiment.
Fundamentals
| Market cap | $1.04B | Enterprise value | $2.82B | Trailing P/E | — | Forward P/E | 5.16 |
| PEG | 0.67 | Price / book | 1.00 | Beta | 1.21 | Dividend yield | 0.00% |
| Revenue growth | 0.8% | Earnings growth | — | Gross margin | 56.9% | Operating margin | 9.6% |
| Profit margin | -0.4% | ROE | -0.7% | ROA | 2.8% | Debt / equity | 1.96 |
| Current ratio | 3.60 | Free cash flow | $94.40M | Analyst recommendation | hold | Mean target | $18.38 |
| 52w high | $20.49 | 52w low | $8.70 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $419M | $392M | $435M | $402M | $416M |
| Op margin | 4.6% | 2.9% | 5.3% | 2.9% | -0.3% |
| Net income | $4.5M | -$4.6M | -$1.7M | -$5.4M | -$484M |
| Gross margin | 52.5% | 55.4% | 50.8% | 51.5% | 50.4% |
| Gross profit | $220M | $217M | $221M | $207M | $209M |
| Operating income | $19.3M | $11.5M | $23.0M | $11.8M | -$1.3M |
- Revenue +7% vs prior quarter ($419M vs $392M).
- Gross margin 52.5% (was 55.4% prior quarter).
- Operating margin expanded to 4.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.6B | $1.6B | $1.5B | $1.6B | — |
| Op margin | 1.1% | 1.8% | 7.2% | 15.3% | — |
| Net income | -$516M | -$6.9M | $67.7M | $181M | — |
| Gross margin | 50.9% | 54.8% | 57.4% | 62.3% | — |
| Gross profit | $832M | $882M | $885M | $970M | — |
| Operating income | $18.0M | $28.4M | $112M | $239M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Integra LifeSciences Holdings (IART) Cuts 2026 Revenue Outlook, Is The Stock Below Fair Value?
2026-10-06 · Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026
2026-10-05 · Nasdaq Hits Fresh Highs While Dow Slips and Small Caps Struggle for Direction
2026-10-05 · 3 Small-Cap Stocks We Approach with Caution
2026-10-03 · Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
2026-10-02 · Why Integra LifeSciences (IART) Stock Is Nosediving
2026-10-02 · Sector Update: Healthcare Stocks Steady Late Afternoon
2026-10-02 · Sector Update: Healthcare Stocks Softer in Afternoon Trading
2026-10-02 · Integra LifeSciences lowers revenue and earnings outlook for 2026
2026-10-02 · Sector Update: Healthcare Stocks Edge Higher Pre-Bell Friday
2026-10-02 · Integra LifeSciences Reports Preliminary Q3 Results, Lowers Full-Year Guidance; Shares Fall 11% Pre-Bell
2026-10-02 · Integra LifeSciences Launches $600 Million Senior Secured Term Loan B
Price (daily)
Full chart · RSI · MACD · patterns